DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques

Immunol Lett. 2001 Nov 1;79(1-2):47-55. doi: 10.1016/s0165-2478(01)00265-6.

Abstract

Rhesus macaques immunized with the HIV-1 SF162DeltaV2 gp140 envelope using the DNA-prime plus protein-boost vaccination methodology, developed HIV envelope-specific T-cell lymphoproliferative responses and potent neutralizing antibodies. To evaluate the protective potential of these antibodies during acute infection, the animals were depleted of their CD8+ T lymphocytes using specific monoclonal antibodies and subsequently challenged intravenously with the pathogenic SHIV(SF162P4) isolate. As compared to non-vaccinated animals (one of which died from AIDS 16 weeks post-exposure) the vaccinated macaques had lower levels of peak viremia, rapidly cleared virus from the periphery and developed delayed seroconversion to SIV core antigens.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS Vaccines / pharmacology*
  • Animals
  • CD8-Positive T-Lymphocytes / immunology
  • Gene Products, env / genetics
  • Gene Products, env / immunology*
  • HIV Antibodies / biosynthesis*
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • HIV-1 / isolation & purification
  • Lymphocyte Activation
  • Lymphocyte Depletion
  • Macaca mulatta / immunology*
  • Neutralization Tests
  • SAIDS Vaccines / pharmacology
  • Sequence Deletion
  • Simian Immunodeficiency Virus / immunology
  • T-Lymphocytes / immunology
  • Vaccines, DNA / pharmacology*
  • env Gene Products, Human Immunodeficiency Virus

Substances

  • AIDS Vaccines
  • Gene Products, env
  • HIV Antibodies
  • SAIDS Vaccines
  • Vaccines, DNA
  • env Gene Products, Human Immunodeficiency Virus
  • gp140 envelope protein, Human immunodeficiency virus 1